Publication | Closed Access

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

OncologyHepatologyα-Fetoprotein ConcentrationsClinical TrialsPathologyLiver DiseaseLiver CancerCancer TreatmentMedicineRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular CarcinomaHealth Sciences